

AWARD NUMBER: W81XWH-19-2-0015

TITLE: Toward Intradermal/Subcutaneous Delivery of Whole Sporozoites for Plasmodium falciparum Malaria Vaccines

PRINCIPAL INVESTIGATOR: Marion Avril, PhD

CONTRACTING ORGANIZATION: MALARVX, INC., Seattle, WA

REPORT DATE: August 2020

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE August 2020			2. REPORT TYPE Annual		3. DATES COVERED 01May2019-30Apr2020	
4. TITLE AND SUBTITLE Toward Intradermal/Subcutaneous Delivery of Whole Sporozoites for Plasmodium falciparum Malaria Vaccines					5a. CONTRACT NUMBER W81XWH-19-2-0015	
					5b. GRANT NUMBER PR182249	
					5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Marion Avril, PhD E-Mail: mavril@malarvx.com					5d. PROJECT NUMBER	
					5e. TASK NUMBER	
					5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) MalarVx 1616 Eastlake Ave E Suite 285 Seattle, WA 98102					8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012					10. SPONSOR/MONITOR'S ACRONYM(S)	
					11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited						
13. SUPPLEMENTARY NOTES						
14. ABSTRACT Work on the proposed Specific Aims in the SOW has not commenced. Research and Development activity on Grant PR182249 was delayed due to the impacts of SARS-Cov-2, and the unexpected passing of Anil Ghosh, PhD, Program Principal Investigator (PI). MalarVx anticipates the grant to be active as of November 1, 2020.						
15. SUBJECT TERMS None listed.						
16. SECURITY CLASSIFICATION OF:				17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT	b. ABSTRACT	c. THIS PAGE	19b. TELEPHONE NUMBER (include area code)			
Unclassified	Unclassified	Unclassified	Unclassified	4		

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4
4. Impact	4
5. Changes/Problems	4
6. Products	4
7. Participants & Other Collaborating Organizations	4
8. Special Reporting Requirements	4
9. Appendices	4

REPORT

1. Introduction

“Towards Intradermal/Subcutaneous Delivery of Whole Sporozoites for *Plasmodium falciparum* Malaria Vaccines.” Our goal is to identify an administration route alternative to intravenous injection that provides high vaccine efficacy after *Plasmodium* challenge.

2. Keywords

Malaria, Vaccine, Sporozoites, Plasmodium, delivery route of administration

3. Accomplishments

Work on the proposed Specific Aims in the SOW has not commenced. Research and Development activity on Grant PR182249 was delayed due to the impacts of SARS-Cov-2, and the unexpected passing of Anil Ghosh, PhD, Program Principal Investigator (PI). MalarVx anticipates the grant to be active as of November 1, 2020.

4. Impact

Nothing to Report.

5. Changes/Problems

Nothing to Report.

6. Products

Nothing to Report.

7. Participants & Other Collaborating Organizations

Nothing to Report.

8. Special Reporting Requirements

Nothing to Report.

9. Appendices

None